Imara to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
05 janv. 2022 07h00 HE
|
Imara, Inc.
BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat subjects...
New gene therapy could provide cure for sickle cell disease, according to UAB study
17 déc. 2021 10h36 HE
|
University of Alabama at Birmingham
BIRMINGHAM, Ala., Dec. 17, 2021 (GLOBE NEWSWIRE) -- New research from University of Alabama at Birmingham, published in the New England Journal of Medicine, suggests a gene therapy called...
Imara Presents Preclinical Data on IMR-261 at the American Society of Hematology (ASH) Annual Meeting 2021
14 déc. 2021 07h00 HE
|
Imara, Inc.
Oral presentation provides first look at new program, IMR-261, a novel, oral, clinic-ready nuclear factor erythroid 2-related factor 2 (Nrf2) activator SCD Townes mouse model demonstrates IMR-261...
Protecting the brain in sickle cell anemia: the value of beginning early in life
06 déc. 2021 10h00 HE
|
Experimental Biology and Medicine
WASHINGTON, Dec. 06, 2021 (GLOBE NEWSWIRE) -- A recently published article in Experimental Biology and Medicine (Volume 246, Issue 23, December, 2021) highlights the importance of early-in-life...
Imara Announces Primary Endpoint Change in the Ardent Phase 2b Clinical Trial of Tovinontrine (IMR-687) in Sickle Cell Disease
22 nov. 2021 07h00 HE
|
Imara, Inc.
Primary endpoint to be changed to annualized rate of VOCs following written U.S. Food and Drug Administration recommendation No change to conduct or size of trial planned; Ardent trial remains on...
Imara Reports Third Quarter 2021 Financial Results and Business Highlights
09 nov. 2021 07h00 HE
|
Imara, Inc.
Interim analysis data for Phase 2b clinical trials of tovinontrine (IMR-687) in patients with beta-thalassemia and sickle cell disease expected in fourth quarter of 2021 Introduction of pipeline...
Imara to Webcast Conference Call of Third Quarter 2021 Financial Results and Business Highlights
04 nov. 2021 16h01 HE
|
Imara, Inc.
BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara to Participate in Upcoming Investor Conferences
15 sept. 2021 07h00 HE
|
Imara, Inc.
BOSTON, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara to Present at Upcoming Investor Conferences
03 sept. 2021 07h00 HE
|
Imara, Inc.
BOSTON, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara Reports Second Quarter 2021 Financial Results and Business Highlights
06 août 2021 07h00 HE
|
Imara, Inc.
Accelerated enrollment in Phase 2b trials in sickle cell disease and beta-thalassemia; interim analyses expected in fourth quarter of 2021 Positive IMR-687 data in sickle cell disease presented at...